Literature DB >> 19597910

In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization.

G Boivin1, D Farlay, M T Khebbab, X Jaurand, P D Delmas, P J Meunier.   

Abstract

UNLABELLED: In postmenopausal osteoporotic women and up to 3 years of treatment with strontium ranelate, strontium was present only in recently deposited bone tissue resulting from formation activity during the period of treatment. Strontium was shown to be dose-dependently deposited into this newly formed bone with preservation of the mineralization.
INTRODUCTION: Interactions between strontium (Sr) and bone mineral and its effects on mineralization were investigated in women treated with strontium ranelate.
METHODS: Bone biopsies from osteoporotic women were obtained over 5-year strontium ranelate treatment from phases II and III studies. Bone samples obtained over 3-year treatment were investigated by X-ray microanalysis for bone Sr uptake and focal distribution, and by quantitative microradiography for degree of mineralization. On some samples, Sr distribution (X-ray cartography) was analyzed on whole sample surfaces and the percentage of bone surface containing Sr was calculated. Bone Sr content was chemically measured on whole samples.
RESULTS: In treated women, Sr was exclusively present in bone formed during treatment; Sr deposition depended on the dose with higher focal content in new bone structural units than in old ones constantly devoid of Sr, even after 3-year treatment. A plateau in global bone Sr content was reached after 3 years of treatment. Cartography illustrated the extent of surfaces containing Sr, and formation activity during strontium ranelate treatment was higher in cancellous than in cortical bone. Mineralization was maintained during treatment.
CONCLUSION: The quality of bone mineral was preserved after treatment with strontium ranelate, supporting the safety of this agent at the bone tissue level.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597910     DOI: 10.1007/s00198-009-1005-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  36 in total

1.  Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment.

Authors:  Barbara M Misof; Paul Roschger; Felicia Cosman; Etah S Kurland; Walter Tesch; Phaedra Messmer; David W Dempster; Jeri Nieves; Elizabeth Shane; Peter Fratzl; Klaus Klaushofer; John Bilezikian; Robert Lindsay
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

Review 2.  Mechanisms of action and therapeutic potential of strontium in bone.

Authors:  P J Marie; P Ammann; G Boivin; C Rey
Journal:  Calcif Tissue Int       Date:  2001-09       Impact factor: 4.333

3.  Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone.

Authors:  Delphine Farlay; Georges Boivin; Gérard Panczer; Agnès Lalande; Pierre Jean Meunier
Journal:  J Bone Miner Res       Date:  2005-04-27       Impact factor: 6.741

4.  Induction of a program gene expression during osteoblast differentiation with strontium ranelate.

Authors:  Ling-Ling Zhu; Samir Zaidi; Yuanzhen Peng; Hang Zhou; Baljit S Moonga; Alexia Blesius; Isabelle Dupin-Roger; Mone Zaidi; Li Sun
Journal:  Biochem Biophys Res Commun       Date:  2007-01-30       Impact factor: 3.575

5.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

6.  Incorporation and distribution of strontium in bone.

Authors:  S G Dahl; P Allain; P J Marie; Y Mauras; G Boivin; P Ammann; Y Tsouderos; P D Delmas; C Christiansen
Journal:  Bone       Date:  2001-04       Impact factor: 4.398

7.  Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women.

Authors:  G Boivin; P Lips; S M Ott; K D Harper; S Sarkar; K V Pinette; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

8.  Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants.

Authors:  S D Bain; C Jerome; V Shen; I Dupin-Roger; P Ammann
Journal:  Osteoporos Int       Date:  2008-12-19       Impact factor: 4.507

9.  Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells.

Authors:  A Barbara; P Delannoy; B G Denis; P J Marie
Journal:  Metabolism       Date:  2004-04       Impact factor: 8.694

10.  Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength.

Authors:  Patrick Ammann; Isabelle Badoud; Sébastien Barraud; Romain Dayer; René Rizzoli
Journal:  J Bone Miner Res       Date:  2007-09       Impact factor: 6.741

View more
  30 in total

1.  The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

Authors:  E T Middleton; S A Steel; M Aye; S M Doherty
Journal:  Osteoporos Int       Date:  2011-01-28       Impact factor: 4.507

2.  Bone: Strontium ranelate does not have an anabolic effect on bone.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Nat Rev Endocrinol       Date:  2013-10-22       Impact factor: 43.330

3.  Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.

Authors:  Jean-Yves Reginster; Mickaël Hiligsmann; Olivier Bruyere
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

4.  Strontium does accumulate in bone.

Authors:  I Fogelman; G M Blake
Journal:  Osteoporos Int       Date:  2011-07-14       Impact factor: 4.507

5.  An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.

Authors:  Mark S Rybchyn; Michael Slater; Arthur D Conigrave; Rebecca S Mason
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

6.  Strontium ranelate stimulates trabecular bone formation in a rat tibial bone defect healing process.

Authors:  C Lavet; G Mabilleau; D Chappard; R Rizzoli; P Ammann
Journal:  Osteoporos Int       Date:  2017-09-28       Impact factor: 4.507

Review 7.  Bone mineralization: from tissue to crystal in normal and pathological contexts.

Authors:  Y Bala; D Farlay; G Boivin
Journal:  Osteoporos Int       Date:  2012-12-11       Impact factor: 4.507

Review 8.  Site specific measurements of bone formation using [18F] sodium fluoride PET/CT.

Authors:  Glen M Blake; Tanuj Puri; Musib Siddique; Michelle L Frost; Amelia E B Moore; Ignac Fogelman
Journal:  Quant Imaging Med Surg       Date:  2018-02

9.  Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats.

Authors:  Y F Li; E Luo; G Feng; S S Zhu; J H Li; J Hu
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

10.  Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.

Authors:  René Rizzoli; Michel Laroche; Marc-Antoine Krieg; Isolde Frieling; Thierry Thomas; Pierre Delmas; Dieter Felsenberg
Journal:  Rheumatol Int       Date:  2010-05-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.